Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Return on Capital Employed of 32.19% for Q1 2026, up 1151.0% year-over-year from 2.57% in Q1 2025, and up 24.39% quarter-over-quarter from 42.57% in Q4 2025.
Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Return on Capital Employed for 6 consecutive years, with 32.19% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1151.0% year-over-year to 32.19%; the TTM figure through Mar 2026 stood at 32.19% (up 1151.0% YoY), while the FY2025 annual figure was 39.49%, up 1463.0% from the prior year.
- Return on Capital Employed advanced to 32.19% in Q1 2026 per IKT's latest filing, from 42.57% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 32.19% in Q1 2026 and bottomed at 1184.15% in Q3 2024.
- Historically, Return on Capital Employed has averaged 173.62% across 5 years, with a median of 76.21% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 106890 bps — and 2025, when it jumped 111821 bps.
- Inhibikase Therapeutics' Return on Capital Employed stood at 78.6% in 2022, then slumped by 100 bps to 157.5% in 2023, then surged by 62 bps to 59.87% in 2024, then increased by 29 bps to 42.57% in 2025, then rose by 24 bps to 32.19% in 2026.
- Business Quant data shows IKT's Return on Capital Employed at 32.19% in Q1 2026, 42.57% in Q4 2025, and 65.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -41.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.36% |
| Mar 31, 2026 | -32.19% |
| Dec 31, 2025 | -42.57% |
| Sep 30, 2025 | -65.95% |
| Jun 30, 2025 | -53.39% |
| Mar 31, 2025 | -43.70% |
| Dec 31, 2024 | -59.87% |
| Sep 30, 2024 | -1,184.15% |
| Jun 30, 2024 | -304.43% |
| Mar 31, 2024 | -235.64% |
| Dec 31, 2023 | -157.50% |
| Sep 30, 2023 | -115.25% |
| Jun 30, 2023 | -87.76% |
| Mar 31, 2023 | -76.21% |
| Dec 31, 2022 | -78.60% |
| Sep 30, 2022 | -67.09% |
| Dec 31, 2021 | -36.81% |
| Sep 30, 2021 | -24.37% |
| Jun 30, 2021 | -24.86% |
| Mar 31, 2021 | -50.35% |